Journal of Internal Medicie and Patient Care

Articles in Press

  • Case report - Medical Published: Jun 23, 2017

    Pembrolizumab Associated Hypothyroidism: Case Report and Review of Literature

    Pembrolizumab is a Programmed Death 1 (PD-1) inhibitor used to treat advanced malignant melanoma and metastatic non- small cell lung cancer. It was recently approved by United States Food and Drug Administration (FDA) for treatment of unresectable and advanced stage malignant melanoma. The most common side effects of Pembrolizumab noted…

    -Niranjan Tachamo, Saroj Lohani, Salik Nazir, Rishikesh Joshi, and Mrunalini Deshmukh